Posts by: Patricia Inacio, PhD

Patricia Inacio, PhD

Patricia holds her Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She also served as a PhD student research assistant in the Laboratory of Doctor David A. Fidock, Department of Microbiology & Immunology, Columbia University, New York.

December 17, 2018December 17, 2018

Urinary Levels of CD80 Protein Not Suitable to Distinguish Between Types of Kidney Disease, Study Suggests

News

Increased urinary excretion of the CD80 protein was found in all patients with active kidney diseases, including Alport syndrome, in a recent study, rendering the protein an unreliable diagnostic biomarker to ... Read more

August 20, 2018August 20, 2018

Patients’ Stem Cells a Potential New Cell Model for Alport Research, Study Suggests

News

Using induced pluripotent stem cells may help researchers identify the underlying mechanisms of Alport syndrome, according to a new study from Monash University in Austrialia. Researchers developed podocyte-like cells ... Read more

June 25, 2018June 25, 2018

Small Molecule Seen to Slow Alport’s Progression in Mouse Model of Disease

News

A small-inhibitor molecule targeting a protein called lysyl oxidase like-2 or LOXL2 was seen to lessen renal scarring and improve the workings of the kidney in a mouse model ... Read more

June 18, 2018June 18, 2018

EU Grants Bardoxolone Orphan Drug Status as Potential Alport Therapy, Phase 3 Trial Enrolling

News

The European Commission (EC) has granted orphan drug status to bardoxolone methyl (bardoxolone)as a possible treatment for Alport syndrome, the therapy’s developer, Reata Pharmaceuticals, announced. Its effectiveness and safety are ... Read more

May 21, 2018May 21, 2018

Recurrence of Kidney Inflammation a Risk Factor for Kidney Rejection After Transplant, Study Shows

News

In patients with acute kidney inflammation, also known as glomerulonephritis, recurrence of the disease is a significant factor underlying failed kidney transplants, a study suggests. The study, “Clinical Outcomes ... Read more

April 23, 2018April 23, 2018

Variations Between Alport, Pierson Syndromes Explain Kidney Damage Differences

News

While Alport syndrome and Pierson syndrome are two diseases caused by mutations in genes important for the correct functioning of the kidney’s filtration system, the two diseases have different manifestations. ... Read more

April 16, 2018April 16, 2018

Bardoxolone Methyl Continues to Aid Alport Patients with Kidney Disease, New Data Shows

News

New results from the Phase 2/3 CARDINAL trial continue to support the benefits of bardoxolone methyl in improving kidney function in people with chronic kidney disease (CKD) due to ... Read more

March 23, 2018March 23, 2018

New System Proposed for Classifying Collagen IV Gene Disorders as Types of Alport

News

An international group of experts has proposed a new classification system for genetic diseases linked to mutations in the collagen IV a345 molecule, suggesting all conditions are referred to as ... Read more

March 14, 2018March 14, 2018

Tailored Chemo Doses Proved Successful for Alport Patient with Breast Cancer in Case Report

News

A case report about an Alport syndrome patient with end-stage renal disease diagnosed with early breast cancer emphasizes the need for communication between nephrologists and oncologists to tackle both diseases ... Read more

November 17, 2017November 17, 2017

Reata’s Bardoxolone Methyl Benefits Patients with Chronic Kidney Disease, TSUBAKI Trial Shows

News

Kyowa Hakko Kirin, a partner company of Reata Pharmaceuticals, presented positive results from its TSUBAKI study showing that Reata’s investigational therapy bardoxolone methyl significantly improved kidney function in patients ... Read more